SCYNEXIS Stock

SCYNEXIS EBITDA per Share

The EBITDA per Share of SCYNEXIS (SCYX) as of Sep 4, 2026 is -0.77 USD. In the previous year, EBITDA per Share was 1.50 USD — a change of -150.95% (lower).

EBITDA per Share

-0.77USD

YoY

-150.95%

Last updated:

EBITDA per Share of SCYNEXIS is 2026 -0.77 USD. EBITDA per Share of SCYNEXIS was 2025 1.50 USD. It decreases by -150.95% lower compared to the previous year.

The SCYNEXIS EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
-9.86 USD
Jan 1, 2018
-6.83 USD
Jan 1, 2019
-8.72 USD
Jan 1, 2020
-4.77 USD
Jan 1, 2021
-2.31 USD
Jan 1, 2022
-2.01 USD
Jan 1, 2023
1.50 USD
Jan 1, 2024
-0.77 USD
The SCYNEXIS EBITDA per Share history
YEAREBITDA per ShareYoY
-0.77USD-150.95%
1.50USD-174.61%
-2.01USD-12.72%
-2.31USD-51.67%
-4.77USD-45.28%
-8.72USD+27.69%
-6.83USD-30.72%
-9.86USD-32.68%
-14.64USD-36.99%
-23.24USD-9.59%
-25.70USD
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

EBITDA per Share of SCYNEXIS is -0.77 USD in 2026.

EBITDA per Share of SCYNEXIS changed from 1.50 USD to -0.77 USD, representing a -150.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

Income Statement — SCYNEXIS

All Key Metrics — SCYNEXIS